• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Valneva SE

    11/16/22 9:59:56 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VALN alert in real time by email
    SC 13D 1 tm2230677d1_sc13d.htm SC 13D

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934
    (Amendment No.     )*

     

    Valneva SE

    (Name of Issuer)

     

    Ordinary Shares, nominal value €0.15 per share

    (Title of Class of Securities)

     

    92025Y103 (American Depositary Shares, each representing two ordinary shares)

    (CUSIP Number)

     

    Sophie Paquin

    Bpifrance Participations S.A.

    6-8, boulevard Haussmann

    75009 Paris

    France

    +33 1 53 89 55 73

     

    With copy to:

    John C. Partigan

    Nixon Peabody LLP

    799 9th Street NW, Suite 500

    Washington, DC 20001

    (202) 585-8000

    ((Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    June 23, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box x.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     

     

     

     

    CUSIP No. 92025Y103
      1 Name of Reporting Person
    Bpifrance Participations S.A.
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
      3 SEC Use Only
      4 Source of Funds
    WC
      5 Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
      6 Citizenship or Place of Organization
    France
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7 Sole Voting Power
    0
     
    8 Shared Voting Power
    9,547,269 Ordinary Shares; 17,004,054 Voting Rights
     
    9 Sole Dispositive Power
    0
     
    10 Shared Dispositive Power
    9,547,269 Ordinary Shares; 17,004,054 Voting Rights
     
      11 Aggregate Amount Beneficially Owned by Each Reporting Person
    9,547,269 Ordinary Shares; 17,004,054 Voting Rights
     
      12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  ¨
     
      13 Percent of Class Represented by Amount in Row (11)
    6.9% of the Ordinary Shares; 10.6% of the Voting Rights1 
     
      14 Type of Reporting Person (See Instructions)
    OO
               

     
    1 Percentage of class is calculated based on 138,354,982 Ordinary Shares outstanding and 160,908,132 Voting Rights as of October 31, 2022, as reported by Valneva SE on November 4, 2022.

     

    Page 2 of 10 Pages

     

     

    CUSIP No. 92025Y103
      1 Name of Reporting Person
    Caisse des dépôts et consignations
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
      3 SEC Use Only
      4 Source of Funds
    WC
      5 Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
      6 Citizenship or Place of Organization
    France
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7 Sole Voting Power
    2,069,552 Ordinary Shares; 2,069,552 Voting Rights
     
    8 Shared Voting Power
    9,547,269 Ordinary Shares; 17,004,054 Voting Rights
     
    9 Sole Dispositive Power
    2,069,552 Ordinary Shares; 2,069,552 Voting Rights
     
    10 Shared Dispositive Power
    9,547,269 Ordinary Shares; 17,004,054  Voting Rights
     
      11 Aggregate Amount Beneficially Owned by Each Reporting Person
    11,616,821 Ordinary Shares; 19,073,606 Voting Rights
     
      12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  ¨
     
      13 Percent of Class Represented by Amount in Row (11)
    8.4% of the Ordinary Shares; 11.8% of the Voting Rights2 
     
      14 Type of Reporting Person (See Instructions)
    OO
               

     
    2 Percentage of class is calculated based on 138,354,982 Ordinary Shares outstanding and 160,908,132 Voting Rights as of October 31, 2022, as reported by Valneva SE on November 4, 2022.

     

     

    Page 3 of 10 Pages

     

     

    CUSIP No. 92025Y103
      1 Name of Reporting Person
    EPIC Bpifrance
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
      3 SEC Use Only
      4 Source of Funds
    WC
      5 Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
      6 Citizenship or Place of Organization
    France
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7 Sole Voting Power
    0
     
    8 Shared Voting Power
    9,547,269 Ordinary Shares; 17,004,054 Voting Rights
     
    9 Sole Dispositive Power
    0
     
    10 Shared Dispositive Power
    9,547,269 Ordinary Shares; 17,004,054 Voting Rights
     
      11 Aggregate Amount Beneficially Owned by Each Reporting Person
    9,547,269 Ordinary Shares; 17,004,054 Voting Rights
     
      12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  ¨
     
      13 Percent of Class Represented by Amount in Row (11)
    6.9% of the Ordinary Shares; 10.6% of the Voting Rights3 
     
      14 Type of Reporting Person (See Instructions)
    OO
               

     
    3 Percentage of class is calculated based on 138,354,982 Ordinary Shares outstanding and 160,908,132 Voting Rights as of October 31, 2022, as reported by Valneva SE on November 4, 2022.

     

    Page 4 of 10 Pages

     

     

    CUSIP No. 92025Y103
      1 Name of Reporting Person
    Bpifrance S.A.
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
      3 SEC Use Only
      4 Source of Funds
    WC
      5 Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
      6 Citizenship or Place of Organization
    France
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7 Sole Voting Power
    0
     
    8 Shared Voting Power
    9,547,269 Ordinary Shares; 17,004,054 Voting Rights
     
    9 Sole Dispositive Power
    0
     
    10 Shared Dispositive Power
    9,547,269 Ordinary Shares; 17,004,054 Voting Rights
     
      11 Aggregate Amount Beneficially Owned by Each Reporting Person
    9,547,269 Ordinary Shares; 17,004,054 Voting Rights
     
      12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  ¨
     
      13 Percent of Class Represented by Amount in Row (11)
    6.9% of the Ordinary Shares; 10.6% of the Voting Rights4 
     
      14 Type of Reporting Person (See Instructions)
    OO
               

     

    4 Percentage of class is calculated based on 138,354,982 Ordinary Shares outstanding and 160,908,132 Voting Rights as of October 31, 2022, as reported by Valneva SE on November 4, 2022.

     

    Page 5 of 10 Pages

     

     

    Item 1. Security and Issuer.

     

    This Schedule 13D (the “Schedule 13D”) relates to the Ordinary Shares, nominal value €0.15 per share (the “Ordinary Shares”) of Valneva SE (the “Issuer”). The Issuer’s principal executive offices are located at 6 rue Alain Bombard, 44800 Saint-Herblain, France.

     

    Item 2. Identity and Background.

     

    This Schedule 13D is filed jointly by (i) Bpifrance Participations S.A., a société anonyme incorporated under the laws of the Republic of France (“Bpifrance Participations”), (ii) Caisse des dépôts et consignations, a French special public entity (établissement spécial) (“CDC”), (iii) EPIC Bpifrance, a French public institution of industrial and commercial nature (“EPIC”), and (iv) Bpifrance S.A. (“Bpifrance”), a société anonyme incorporated under the laws of the Republic of France. Bpifrance Participations, CDC, EPIC and Bpifrance are referred to herein collectively as the “Reporting Persons.” The principal address for Bpifrance Participations, EPIC and Bpifrance is 27-31, avenue du Général Leclerc, 94710 Maisons-Alfort Cedex, France. The principal address for CDC is 56, rue de Lille, 75007 Paris, France.

     

    Bpifrance Participations is a French public investment entity specializing in the business of equity financing via direct investments or fund of funds. Bpifrance Participations is a subsidiary owned at 99.99% by Bpifrance, a French credit institution. CDC and EPIC each hold 49.2% of the share capital of Bpifrance and jointly control Bpifrance. CDC is principally engaged in the business of long-term investments. EPIC, a French public institution of industrial and commercial nature, is principally engaged in the business of banking finance.

     

    Bpifrance may be deemed to be the beneficial owner of shares held by Bpifrance Participations indirectly through its 99.99% ownership of Bpifrance Participations. CDC and EPIC may be deemed to be the beneficial owners of shares held by Bpifrance Participations indirectly through their joint ownership and control of Bpifrance.

     

    Attached as Appendices A, B, C and D to Item 2 is information concerning the executive officers and directors of Bpifrance Participations, CDC, EPIC and Bpifrance, respectively, required to be disclosed in response to Item 2 and General Instruction C to Schedule 13D.

     

    None of the Reporting Persons, nor, to the best of their knowledge, any of the persons referred to in Appendices A, B, C and D to Item 2 has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

     

    Item 3.Source and Amount of Funds or Other Consideration.

     

    Bpifrance Participations used its working capital to purchase the Ordinary Shares.

     

    Item 4. Purpose of Transaction.

     

    Ownership is stated as of November 15, 2022 and the ownership percentages are calculated based on 138,354,982 Ordinary Shares outstanding and 160,908,13 Voting Rights as of October 31, 2022, as reported by the Issuer on November 4, 2022.

     

    All of the Ordinary Shares that are held of record by the Reporting Persons as reported herein were acquired for investment purposes. The Reporting Persons retain the right to change their investment intent, from time to time to acquire additional Ordinary Shares or other securities of the Issuer, or to sell or otherwise dispose of all or part of the Ordinary Shares or other securities of the Issuer, if any, beneficially owned by them, in any manner permitted by law. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein.

     

    Page 6 of 10 Pages

     

     

    Except as set forth above, none of the Reporting Persons currently has any plans or proposals which would be related to or would result in any of the matters described in Items 4(a)-(j) of the Instructions to Schedule 13D. However, as part of the ongoing evaluation of investment and investment alternatives, the Reporting Persons may consider such matters and, subject to applicable law, may formulate a plan with respect to such matters, and, from time to time, may hold discussions with or make formal proposals to management or the board of directors of the Issuer or other third parties regarding such matters.

     

    Item 5. Interest in Securities of the Issuer.

     

    Please see Items 5, 6, 7, 8, 9 and 11 of each cover sheet for each filing entity.

     

    As of November 15, 2022, (i) Bpifrance Participations held directly 9,547,269 Ordinary Shares and 17,004,054 Voting Rights, and (ii) CDC Croissance S.A., a wholly-owned subsidiary of CDC (“CDC Croissance”), held directly 2,069,552 Ordinary Shares and 2,069,552 Voting Rights. Neither Bpifrance nor EPIC held any Ordinary Shares directly.  Bpifrance may be deemed to be the beneficial owner of 9,547,269 Ordinary Shares and 17,004,054 Voting Rights indirectly through its 99.99% ownership of Bpifrance Participations. EPIC may be deemed to be the beneficial owner of 9,547,269 Ordinary Shares and 17,004,054 Voting Rights indirectly through its joint ownership and control of Bpifrance. CDC may be deemed to be the beneficial owner of (x) 11,616,821 Ordinary Shares and 19,073,606 Voting Rights, indirectly through its joint ownership and control of Bpifrance and (y) 2,069,552 Ordinary Shares and 2,069,552 Voting Rights, indirectly through its ownership of CDC Croissance.

     

    The ownership percentages are calculated based on 138,354,982 Ordinary Shares outstanding and 160,908,13 Voting Rights as of October 31, 2022, as reported by the Issuer on November 4, 2022.

     

    (a) See also the information contained on the cover pages of this Schedule 13D, which is incorporated herein by reference.

     

    (b) See the information contained on the cover pages of this Schedule 13D, which is incorporated herein by reference.

     

    (c) There have been no reportable transactions with respect to the Ordinary Shares of the Issuer within the last 60 days by the Reporting Persons other than as described in this Schedule 13D below:

     

    Bpifrance Participations effected the following transactions:

     

    Date  Transaction  Amount of
    Shares
       Average Per
    Share Price
    (EUR)
       How Effected
    09/29/2022  Purchase   1,020,408    4.9   Capital Increase
    11/11/2022  Sale   -10,838    7.0107       Open Market
    11/14/2022  Sale   -64,454    7.1347       Open Market
    11/15/2022  Sale   -17,325    7.0548       Open Market

     

    Page 7 of 10 Pages

     

     

    Caisse des dépôts et consignations effected the following transactions:

     

    Date  Transaction  Amount of
    Shares
       Average Per
    Share Price
    (EUR)
       How Effected
    09/13/2022  Purchase   10,820    8.4   Open Market
    09/14/2022  Purchase   55,773    8.3243   Open Market
    09/15/2022  Purchase   20,738    8.3773   Open Market
    09/16/2022  Purchase   34,569    8.215   Open Market
    09/30/2022  Purchase   259,516    4.9   Open Market
    09/30/2022  Purchase   432,526    4.9   Open Market
    09/30/2022  Purchase   40,000    5.1636   Open Market
    09/30/2022  Purchase   80,000    5.1636   Open Market
    10/03/2022  Purchase   20,000    5.2831   Open Market
    10/04/2022  Purchase   20,000    5.5851   Open Market
    10/05/2022  Purchase   18,400    5.6708   Open Market
    10/06/2022  Purchase   8,876    5.6996   Open Market
    10/18/2022  Purchase   25,000    6.7275   Open Market
    10/19/2022  Purchase   24,998    6.3927   Open Market
    10/20/2022  Purchase   25,001    6.2483   Open Market
    10/21/2022  Purchase   25,001    6.3451   Open Market
    10/24/2022  Purchase   138    6.4985   Open Market
    10/25/2022  Purchase   3,318    6.4354   Open Market
    10/26/2022  Purchase   1,415    6.4812   Open Market
    10/27/2022  Purchase   10,065    6.6893   Open Market
    10/29/2022  Purchase   10,064    6.6176   Open Market

     

    (d) Not applicable.

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    During the Issuer’s Annual General Meeting held on June 23, 2022, the Issuer’s shareholders appointed two new Supervisory Board members, one of which was Bpifrance Participations, for a three-year term. The representative for Bpifrance Participations is Maïlys Ferrère, who is a Director of Large Venture Investments at Bpifrance Participations.

     

    Page 8 of 10 Pages

     

     

    Item 7.Material to Be Filed as Exhibits.
         
    Exhibit   Description
    99.1   Joint Filing Agreement, dated as of November 15, 2022, by and among the Reporting Persons.

     

    Page 9 of 10 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: November 15, 2022

     

      Bpifrance Participations S.A.
           
      By: /s/ Sophie Paquin
      Name: Sophie Paquin
      Title: Director of Legal Affairs
         
      Caisse des dépôts et consignations
           
      By: /s/ Laurence Giraudon
      Name: Laurence Giraudon
      Title: Chief Operating Officer, Finance and Operations Department, Asset Management Division
         
      EPIC Bpifrance
         
      By: /s/ Sophie Paquin
      Name: Sophie Paquin
      Title: Director of Legal Affairs
           
      Bpifrance S.A.
           
      By: /s/ Boubakar Dione
      Name: Boubakar Dione
      Title: Group Director of Legal Affairs

     

    Page 10 of 10 Pages

     

     

    APPENDIX A

     

    Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of

     

    BPIFRANCE PARTICIPATIONS S.A.

     

    The name, business address and present principal occupation or employment of each of the directors and executive officers of Bpifrance Participations S.A. are set forth below. The business address of each director and executive officer is Bpifrance Participations S.A., 27-31, avenue du Général Leclerc, 94710 Maisons-Alfort Cedex, France. Unless otherwise indicated, each director and executive officer is a citizen of France.

     

    BOARD OF DIRECTORS

     

    Name   Present Principal Occupation or Employment
    NICOLAS DUFOURCQ   Director, Chairman, Chief Executive Officer of Bpifrance Participations, and Chief Executive Officer of Bpifrance
         
    CAROLE ABBEY DUVAL   Director, Head of the Steering Department of strategic holdings at Caisse des Dépôts
         
    REMI FOURNIAL   Director, Head of M&A at Groupe Caisse des Dépôts
         
    FREDERIC SAINT-GEOURS    Director, Director of Société nationale SNCF
         
    FRENCH STATE, represented by CHARLES SARRAZIN   Director, in charge of shareholding interests in the Service & Finance sectors, Agence des Participations de l’Etat (French State Shareholding Agency) 
         
    CONSTANCE VALIGNY   Director, Assistant Director for macroeconomic policies, Direction Générale du Trésor (French Treasury)
         
    CHLOE MAYENOBE   Director, Chief Growth Officer and General Representative at Solarisbank
         
    VICTOIRE AUBRY   Director, Chief Financial Officer of Icade
         
    CAROLINE PAROT   Director, CEO of Europcar Mobility Group
         
    ROMAIN BONENFANT   Director, Chief, Service of Industry, General Directorate for Companies of the Ministry of Economy and Finance

     

    EXECUTIVE OFFICERS

     

    Name   Present Principal Occupation or Employment
    NICOLAS DUFOURCQ   Chief Executive Officer
         
    JOSÉ GONZALO   Executive Director
         
    PIERRE BENEDETTI   Chief Financial Officer 

     

    1

     

     

    APPENDIX B

     

    Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of

     

    CAISSE DES DÉPÔTS ET CONSIGNATIONS

     

    The name, business address and present principal occupation or employment of each of the members of the Management Committee of Caisse des Dépôts et consignations are set forth below. The business address of each director and executive officer is Caisse des Dépôts et consignations, c/o 56, rue de Lille, 75007 Paris, France. Unless otherwise indicated, each such person is a citizen of France.

     

    MANAGEMENT COMMITTEE

     

    Name    Present Principal Occupation or Employment 
    ERIC LOMBARD   Chief Executive Officer of Caisse des Dépôts et consignations
         
    OLIVIER SICHEL   Deputy Chief Executive Officer of Caisse des Dépôts et consignations
         
    NICOLAS DUFOURCQ   Chief Executive Officer of Bpifrance
         
    VIRGINIE CHAPRON-DU-JEU   Director of Finance for the Caisse des Dépôts et consignations Group
         
    PIERRE CHEVALIER   Head of Legal and Tax Department
         
    NATHALIE TUBIANA   Risk Director of the Caisse des Dépôts et consignations Group
         
    OLIVIER MAREUSE   Chief Investment officer - Director of Savings Funds at Caisse des Dépôts et consignations
         
    CATHERINE MAYENOBE   Secretary General of Caisse des Dépôts et consignations Group
         
    SOPHIE QUATREHOMME   Group Corporate Communications Director
         
    MICHEL YAHIEL   Pensions and Solidarity Director
         
    ANTOINE SAINTOYANT   Director of strategic holdings at Caisse des Dépôts et consignations

     

    2

     

     

    APPENDIX C

     

    Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of

     

    EPIC BPIFRANCE

     

    The name, business address and present principal occupation or employment of each of the directors and executive officers of EPIC Bpifrance are set forth below. The business address of each director and executive officer is EPIC Bpifrance, 27-31, avenue du Général Leclerc, 94710 Maisons-Alfort Cedex, France. Unless otherwise indicated, each director and executive officer is a citizen of France.

     

    DIRECTORS

     

    Name    Present Principal Occupation or Employment 
    CHRISTIAN BODIN   Director, Chairman, Chief Executive Officer of EPIC Bpifrance
         
    PIERRE-LOUIS AUTIN   Director, Head of department SITTAR at the Higher Education, Research and Innovation Ministry
         
    PIERRE CHABROL   Director, Deputy Director at the Directorate of Financing, Industry and Market of the Ministry of Economy and Finance
         
    LOUIS PASQUIER DE FRANCLIEU   Director, Deputy Director at the 3rd General Directorate for Budget of the Ministry of Economy and Finance
         
    VINCENT TEJEDOR  

    Director, Assistant Director in charge of the development of enterprises, General Directorate for Companies of the Ministry of Economy and Finance

         
    EMMANUELLE BENHAMOU   Director, Deputy at the audit and accounting department of the Agence des Participations de l’Etat (French State Shareholding Agency)
         
    GERALDINE LEVEAU   Director, Deputy General Secretary for Public Investment

     

    3

     

     

    APPENDIX D

     

    Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of

     

    BPIFRANCE S.A.

     

    The name, business address and present principal occupation or employment of each of the directors and executive officers of Bpifrance S.A. are set forth below. The business address of each director and executive officer is Bpifrance S.A., 27-31, avenue du Général Leclerc, 94710 Maisons-Alfort Cedex, France. Unless otherwise indicated, each director and executive officer is a citizen of France.

     

    DIRECTORS

     

    Name    Present Principal Occupation or Employment 
    ERIC LOMBARD   Director, Chairman, Chief Executive Officer of the Caisse des Dépôts
         
    NICOLAS DUFOURCQ   Director, Chief Executive Officer of Bpifrance and Director, Chairman and Chief Executive Officer of Bpifrance Participations
         
    ALEXIS ZAJDENWEBER   Director, Chairman of the Agence des Participations de l’Etat (French State Shareholding Agency)
         
    SEBASTIEN RASPILLER   Director, Chief of the service relating to the financing of the economy at the Direction Générale du Trésor (French Treasury)
         
    MARIE DELEAGE   Director representing the employees of Bpifrance
         
    PHILIPPE BAYEUX   Director representing the employees of Bpifrance
         
    VIRGINIE CHAPRON-DU JEU   Director, Director of Finance for the Caisse des Dépôts Group
         
    CLAIRE DUMAS   Director, Finance Director at Société Générale

     

    SOPHIE STABILE   Director, CFO at Groupe Lagardère
         
    CATHERINE LAGNEAU   Director, Deputy Director of the General council of economy
         
    ANTOINE SAINTOYANT   Director, Director of strategic holdings at Caisse des Dépôts
         
    HAROLD HUWART   Director, Vice-president of the Regional Council of Centre-Val-de-Loire, in charge of the economy, farming and associations
         
    CAROLE ABBEY DUVAL     Director, Head of the Steering Department of strategic holdings at Caisse des Dépôts
         
    DIANE SIMIU  

    Director, deputy of the general commissioner for sustainable development at the Ministry for economic and solidarity transition

     

    4

     

    Get the next $VALN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VALN

    DatePrice TargetRatingAnalyst
    8/3/2022$34.00Buy
    H.C. Wainwright
    More analyst ratings

    $VALN
    SEC Filings

    See more
    • SEC Form 6-K filed by Valneva SE

      6-K - Valneva SE (0001836564) (Filer)

      5/27/25 9:04:37 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Valneva SE

      6-K - Valneva SE (0001836564) (Filer)

      5/12/25 1:01:02 PM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Valneva SE

      6-K - Valneva SE (0001836564) (Filer)

      5/7/25 12:11:21 PM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VALN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Valneva to Participate at U.S. and European Investor Conferences in June

      Saint-Herblain (France), May 26, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2025. Key topics for discussion include Valneva's commercial stage vaccines and its differentiated portfolio of vaccine candidates, including VLA15, the world's leading Lyme disease vaccine candidate. VLA15 is partnered with Pfizer and currently being evaluated in a pivotal Phase 3 trial for which the Company expects first data at the end of 2025. Institutional investors who would like to meet 1on1 with management at any of

      5/26/25 11:30:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

      Saint Herblain (France), May, 12 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC), in a joint communication to the medical community, have recommended a pause in the use of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ® in elderly individuals while ongoing investigations into reported serious adverse events (SAEs) are completed. This update follows an earlier recommendation from the U.S. Advisory Committee on Immunization Practices (ACIP) to include a precaution related to the use of IXCHIQ® in persons aged 65 and over and a si

      5/12/25 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

      Saint Herblain (France), May, 07 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ® based on reports of serious adverse events (SAEs) in elderly people. As a temporary measure, while this review is ongoing, EMA has suspended the use of the vaccine for individuals over 65 years old. EMA has maintained current recommendations for IXCHIQ® for people from 12 to 64 years of age. The decision was taken following a plenary meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) on May 5, 2025 and is based on reports of 17

      5/7/25 11:45:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VALN
    Leadership Updates

    Live Leadership Updates

    See more
    • Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

      Saint-Herblain (France), June 26, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting (CGM) held today in Lyon, France. Among the adopted resolutions were approval of the 2023 financial statements, delegations for the management board to increase Valneva's share capital and/or issue financial instruments, and the appointment of a new director to its Board. Ms. Danièle Guyot-Caparros was appointed to Valneva's Board of Directors for a three-year term. Ms. Guyot-Caparros has a proven track record in finance and business

      6/26/24 11:45:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

      Saint-Herblain (France), May 21, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) and Executive Committee member, effective June 3, 2024. Valneva decided to complement its Executive Team with an accomplished R&D leader to oversee the further evolution of the Company´s R&D portfolio. Specifically, Dr. Schuitemaker will focus on accelerating Valneva's pre-clinical and translational R&D activities in support of the Company's strategic ambition to provide first-, best- or only-in-class vaccine solutions. Dr. Schuitemaker brings more than two decades of experience in vacc

      5/21/24 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer's Former Vaccine R&D Head to its Supervisory Board

      Saint-Herblain (France), June 21, 2023 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held today in Lyon, France. Among the adopted resolutions were approval of the 2022 financial statements, delegations for the management board to increase Valneva's share capital and/or issue financial instruments, as well as the appointment of a new Supervisory Board member and the reappointment of two of them. Dr Kathrin U Jansen, Ph.D., a German national with over 30 years of vaccine R&D experience, was appointed to Valneva's Supervisory

      6/21/23 12:15:00 PM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VALN
    Financials

    Live finance-specific insights

    See more
    • Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024Cash and cash equivalents of €153.0 million at end of March 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), May 7, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The condensed consolidated interim financial results are available on the Company's website (Financial Reports – Valneva). Valneva will provide a live webcast of its first quarter 2025 results conference call begi

      5/7/25 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

      Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 million including sale of Priority Review Voucher1, successful private placement and 67% reduction in operating cash burnSubstantial clinical and regulatory progress in 2024; further data readouts, product approvals and label extensions anticipated in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn Saint-Herblain (France), March 20, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its consolidated financial results for the y

      3/20/25 2:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

       Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023 Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement2Lower cash burn expected in the second half of 2024 as cost contributions to the agreed R&D budget for partnered Lyme disease program were completed in the second quarter of the year Full-year 2024 Financial Guidance Narrowed Expected total product sales according to guidan

      11/7/24 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VALN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Valneva SE with a new price target

      H.C. Wainwright initiated coverage of Valneva SE with a rating of Buy and set a new price target of $34.00

      8/3/22 7:27:56 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VALN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Valneva SE

      SC 13D/A - Valneva SE (0001836564) (Subject)

      9/20/24 4:00:37 PM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Valneva SE (Amendment)

      SC 13G/A - Valneva SE (0001836564) (Subject)

      2/14/24 8:59:33 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Valneva SE (Amendment)

      SC 13D/A - Valneva SE (0001836564) (Subject)

      6/30/23 9:00:06 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care